- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Concord Drugs Ltd manufactures licensed drugs based on approved formulationsProduct Portfolio: a) Pharmaceutical Ready to fill Pellets b) Multiple Unit Pellet System (MUPS) c) Tissue Bio Adhesive d) Injectables (Small Volume Parenterals) e) Oral Solid Dosages (Tablets & Capsules) f) Liquid Orals (Syrups & Suspensions) g) Dry Syrup (Powder)
Concord Drugs board approved Q1 results. Standalone revenue at Rs 20.89 Cr, net profit Rs 1.11 Cr. Consolidated revenue Rs 20.94 Cr, net profit Rs 1.11 Cr. EPS improved to Rs 0.85 (Cons.) despite equity dilution from a preferential issue. Strong earnings growth noted.
Concord Drugs Limited has confirmed that its Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, has complied with regulations concerning the dematerialization of securities for the quarter ended 30th June. This ensures that physical share certificates converted to electronic form have been correctly processed, cancelled, and recorded with depositories....
Concord Drugs Limited has closed its trading window effective July 1st for all insiders, including Directors and Designated Employees. This action is taken in preparation for the Board's consideration of the unaudited financial results for the quarter ending June. During this period, insiders and their immediate relatives are restricted from...